Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 14/20 | 0.48 |
| ▸ | MAPK13 | O15264 | 10/20 | 0.48 |
| ▸ | MAPK12 | P53778 | 10/20 | 0.48 |
| ▸ | MAPK11 | Q15759 | 10/20 | 0.48 |
| ▸ | GCGR | P47871 | 7/20 | 0.46 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.44 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.44 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.44 |
| ▸ | LCK | P06239 | 1/20 | 0.44 |
| ▸ | RET | P07949 | 1/20 | 0.44 |
| ▸ | PRKACA | P17612 | 1/20 | 0.44 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.44 |
| ▸ | MATK | P42679 | 1/20 | 0.44 |
| ▸ | FRK | P42685 | 1/20 | 0.44 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.44 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.44 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.44 |
| ▸ | GSK3A | P49840 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 1/20 | 0.44 |
| ▸ | CSNK1G2 | P78368 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1386735 | 0.90 | CYP17A1 (0.44) | MAPK14MAPK13MAPK12MAPK11CSNK1A1 | |
| SCHEMBL1386876 | 0.84 | CYP17A1 (0.42) | MAPK14MAPK13MAPK12MAPK11ALOX5 | |
| SCHEMBL2929829 | 0.84 | RIPK3 (0.49) | MAPK14MAPK13MAPK12MAPK11ALOX5 | |
| SCHEMBL1386741 | 0.82 | ADORA2A (0.45) | MAPK14GSK3BCYP17A1CYP1A2KDM4E | |
| SCHEMBL1386666 | 0.82 | MAPK14 (0.50) | MAPK14MAPK13MAPK12MAPK11GCGR | |
| SCHEMBL2929824 | 0.82 | MAPK14 (0.46) | MAPK14MAPK13MAPK12MAPK11CSNK1A1 | |
| SCHEMBL29652680 | 0.80 | MAPK14 (0.46) | MAPK14MAPK13MAPK12MAPK11CSNK1A1 | |
| SCHEMBL2930582 | 0.79 | SIGMAR1 (0.41) | MAPK14MAPK13MAPK12MAPK11MAP4K4 | |
| SCHEMBL2926310 | 0.78 | MAPK14 (0.48) | MAPK14MAPK13MAPK12MAPK11GCGR | |
| SCHEMBL2930799 | 0.78 | MAPK14 (0.44) | MAPK14MAPK13MAPK12MAPK11MAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8536194-B2 | Pyrazolopyridine derivates | PALAU PHARMA, S.A. (ES) | 2013-09-17 | — | — | US | claimed |
| EP-1611131-B1 | PYRAZOLOPYRIDINE DERIVATES | PALAU PHARMA SA (ES) | 2010-09-15 | — | — | EP | claimed |
| US-20090005377-A1 | Pyrazolopyridine Derivates | PALAU PHARMA, S.A. (ES) | 2009-01-01 | — | — | US | claimed |
| US-7468376-B2 | Pyrazolopyridine derivates | PALAU PHARMA, S.A. (ES) | 2008-12-23 | — | — | US | claimed |
| US-20060167040-A1 | Pyrazolopyridine derivates | J. URIACH Y COMPANIA S.A. (ES) | 2006-07-27 | — | — | US | claimed |
| US-8536194-B2 | Pyrazolopyridine derivates | PALAU PHARMA, S.A. (ES) | 2013-09-17 | — | — | US | disclosed |
| EP-1611131-B1 | PYRAZOLOPYRIDINE DERIVATES | PALAU PHARMA SA (ES) | 2010-09-15 | — | — | EP | disclosed |
| US-20090286983-A1 | Pyrazolopyridine Derivates | PALAU PHARMA, S.A. (ES) | 2009-11-19 | — | — | US | disclosed |
| US-20090005377-A1 | Pyrazolopyridine Derivates | PALAU PHARMA, S.A. (ES) | 2009-01-01 | — | — | US | disclosed |
| US-7468376-B2 | Pyrazolopyridine derivates | PALAU PHARMA, S.A. (ES) | 2008-12-23 | — | — | US | disclosed |
| US-20060167040-A1 | Pyrazolopyridine derivates | J. URIACH Y COMPANIA S.A. (ES) | 2006-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167040-A1 | Pyrazolopyridine derivates | MAPK1, MAP4K2, MAP4K3 | MAPK14 34/4885MAPK13 36/4885MAPK12 38/4885 |
| US-20090286983-A1 | Pyrazolopyridine Derivates | MAPK1, MAPK4, MAP4K2 | MAPK14 33/4885MAPK13 37/4885MAPK12 39/4885 |
| US-20090005377-A1 | Pyrazolopyridine Derivates | MAPK1, MAPK4, MAP4K2 | MAPK14 33/4885MAPK13 37/4885MAPK12 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.